inclusion criteria: * ability to understand and the willingness to sign a written informed consent document * participants with a diagnostically proven covid-19 positive nasal swab test result within 14 days * participants must have a diagnosis of cancer * participants must be considered immune suppressed either due to their cancer diagnosis or due to treatment of their cancer. participants must meet at least one of the following criteria: * have received immune suppressing anti-cancer therapy in the past year (i.e., therapy that suppresses white blood cells and/or has been shown to be associated with infection, as stipulated in the drug package insert) * have received intravenous immunoglobulin (ivig) in the past year for treatment and/or prevention of recurrent infections * are within one year of an autologous bone marrow transplant or chimeric antigen receptor (car) t-cell therapy, or within five years of an allogeneic bone marrow transplant * have been treated for three or more infections within the past 6 months * have an absolute neutrophil count at or below 1,500 cells/mcl at some point within two months of the time of consent. this can be due therapy and/or due to cancer suppressing marrow function * have a history of neutropenic fever in the past year * presence of a chronic infection, e.g. tuberculosis (tb) or osteomyelitis, or within 3 months of treatment for such. topical fungal infections of the skin are not included in this category * participants with mild symptoms, must have had mild symptoms for no more than 2 weeks * participants with moderate symptoms, must have had moderate symptoms for no more than 1 week * pregnant or women of child-bearing potential may be treated if they have no documented lopinavir-associated resistance substitutions * aspartate aminotransferase (ast) (serum glutamic-oxaloacetic transaminase \[sgot\]) and alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 3 x upper limit of normal (uln) * total bilirubin =\< 2 x uln (individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis) * creatinine =\< 2 x uln * participants with abnormal blood counts (white blood cell \[wbc\], platelet, hemoglobin \[hg\]) will not be excluded

inclusion criteria: * ability to understand and the willingness to sign a written informed consent document * participants with a diagnostically proven covid-19 positive nasal swab test result within 14 days * participants must have a diagnosis of cancer * participants must be considered immune suppressed either due to their cancer diagnosis or due to treatment of their cancer. participants must meet at least one of the following criteria: * have received immune suppressing anti-cancer therapy in the past year (i.e., therapy that suppresses white blood cells and/or has been shown to be associated with infection, as stipulated in the drug package insert) * have received intravenous immunoglobulin (ivig) in the past year for treatment and/or prevention of recurrent infections * are within one year of an autologous bone marrow transplant or chimeric antigen receptor (car) t-cell therapy, or within five years of an allogeneic bone marrow transplant * have been treated for three or more infections within the past 6 months * have an absolute neutrophil count at or below 1,500 cells/mcl at some point within two months of the time of consent. this can be due therapy and/or due to cancer suppressing marrow function * have a history of neutropenic fever in the past year * presence of a chronic infection, e.g. tuberculosis (tb) or osteomyelitis, or within 3 months of treatment for such. topical fungal infections of the skin are not included in this category * participants with mild symptoms, must have had mild symptoms for no more than 2 weeks * participants with moderate symptoms, must have had moderate symptoms for no more than 1 week * pregnant or women of child-bearing potential may be treated if they have no documented lopinavir-associated resistance substitutions * aspartate aminotransferase (ast) (serum glutamic-oxaloacetic transaminase \[sgot\]) and alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 3 x upper limit of normal (uln) * total bilirubin =\< 2 x uln (individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis) * creatinine =\< 2 x uln * participants with abnormal blood counts (white blood cell \[wbc\], platelet, hemoglobin \[hg\]) will not be excluded

inclusion criteria: - ability to understand and the willingness to sign a written informed consent document - participants with a diagnostically proven covid-19 positive nasal swab test result within 14 days - participants must have a diagnosis of cancer - participants must be considered immune suppressed either due to their cancer diagnosis or due to treatment of their cancer. participants must meet at least one of the following criteria: - have received immune suppressing anti-cancer therapy in the past year (i.e., therapy that suppresses white blood cells and/or has been shown to be associated with infection, as stipulated in the drug package insert) - have received intravenous immunoglobulin (ivig) in the past year for treatment and/or prevention of recurrent infections - are within one year of an autologous bone marrow transplant or chimeric antigen receptor (car) t-cell therapy, or within five years of an allogeneic bone marrow transplant - have been treated for three or more infections within the past 6 months - have an absolute neutrophil count at or below 1,500 cells/mcl at some point within two months of the time of consent. this can be due therapy and/or due to cancer suppressing marrow function - have a history of neutropenic fever in the past year - presence of a chronic infection, e.g. tuberculosis (tb) or osteomyelitis, or within 3 months of treatment for such. topical fungal infections of the skin are not included in this category - participants with mild symptoms, must have had mild symptoms for no more than 2 weeks - participants with moderate symptoms, must have had moderate symptoms for no more than 1 week - pregnant or women of child-bearing potential may be treated if they have no documented lopinavir-associated resistance substitutions - aspartate aminotransferase (ast) (serum glutamic-oxaloacetic transaminase [sgot]) and alanine aminotransferase (alt) (serum glutamate pyruvate transaminase [sgpt]) =< 3 x upper limit of normal (uln) - total bilirubin =< 2 x uln (individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis) - creatinine =< 2 x uln - participants with abnormal blood counts (white blood cell [wbc], platelet, hemoglobin [hg]) will not be excluded

inclusion criteria: - ability to understand and the willingness to sign a written informed consent document - participants with a diagnostically proven covid-19 positive nasal swab test result within 14 days - participants must have a diagnosis of cancer - participants must be considered immune suppressed either due to their cancer diagnosis or due to treatment of their cancer. participants must meet at least one of the following criteria: - have received immune suppressing anti-cancer therapy in the past year (i.e., therapy that suppresses white blood cells and/or has been shown to be associated with infection, as stipulated in the drug package insert) - have received intravenous immunoglobulin (ivig) in the past year for treatment and/or prevention of recurrent infections - are within one year of an autologous bone marrow transplant or chimeric antigen receptor (car) t-cell therapy, or within five years of an allogeneic bone marrow transplant - have been treated for three or more infections within the past 6 months - have an absolute neutrophil count at or below 1,500 cells/mcl at some point within two months of the time of consent. this can be due therapy and/or due to cancer suppressing marrow function - have a history of neutropenic fever in the past year - presence of a chronic infection, e.g. tuberculosis (tb) or osteomyelitis, or within 3 months of treatment for such. topical fungal infections of the skin are not included in this category - participants with mild symptoms, must have had mild symptoms for no more than 2 weeks - participants with moderate symptoms, must have had moderate symptoms for no more than 1 week - pregnant or women of child-bearing potential may be treated if they have no documented lopinavir-associated resistance substitutions - aspartate aminotransferase (ast) (serum glutamic-oxaloacetic transaminase [sgot]) and alanine aminotransferase (alt) (serum glutamate pyruvate transaminase [sgpt]) =< 3 x upper limit of normal (uln) - total bilirubin =< 2 x uln (individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis) - creatinine =< 2 x uln - participants with abnormal blood counts (white blood cell [wbc], platelet, hemoglobin [hg]) will not be excluded